A 56 week, double-blind, randomised, placebo-controlled trial to determine the efficacy of testosterone, with and without DHA supplementation in PiB positive men with Subjective Memory Complaints as a strategy to prevent the development of Alzheimers Disease.
Latest Information Update: 19 Apr 2021
At a glance
- Drugs Testosterone undecanoate (Primary) ; Docosahexaenoic acid
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms InTrePad
- Sponsors Lawley Pharmaceuticals
- 24 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Jun 2016 New trial record